Scilex Holding (SCLX) Gross Margin (2022 - 2026)

Scilex Holding (SCLX) recorded quarterly Gross Margin of 48.29% in Q1 2026, up 5.0% quarter-over-quarter from 45.99% in Q4 2025, and down 2403.0% on a YoY basis from 2.1% in Q1 2025.

Scilex Holding (SCLX) Gross Margin (2022 - 2026) Analysis & Trends

Scilex Holding's Gross Margin history runs 5 years deep, the most recent figure standing at 48.29% for Q1 2026.

  • In Q1 2026, Gross Margin fell 2403.0% year-over-year to 48.29%; the TTM figure through Mar 2026 stood at 59.69% (down 1224.0% YoY), while the FY2025 annual figure was 65.02%, down 549.0% from the prior year.
  • Gross Margin was 48.29% for Q1 2026 at Scilex Holding, up from 45.99% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 83.21% in Q1 2022 to a low of 45.99% in Q4 2025.
  • Historically, Gross Margin has averaged 67.2% across 5 years, with a median of 66.94% in 2025.
  • The sharpest annual moves came in 2025 and 2026: Gross Margin jumped 760 bps in 2025, then plunged 2403 bps in 2026.
  • A 5-year view of Gross Margin shows it stood at 62.14% in 2022, then grew by 7 bps to 66.42% in 2023, then climbed by 3 bps to 68.52% in 2024, then sank by 33 bps to 45.99% in 2025, then advanced by 5 bps to 48.29% in 2026.
  • The last three Gross Margin figures came in at 48.29% (Q1 2026), 45.99% (Q4 2025), and 68.48% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Gsk 93,026,132.38 Bn 93,026,127.42 Bn 7.76 Bn 75.42%
2 Eli Lilly 1,022.62 Bn 1,017.34 Bn 16.22 Bn 81.93%
3 Johnson & Johnson 570.65 Bn 548.59 Bn 15.96 Bn 66.31%
4 AbbVie 398.73 Bn 389.38 Bn 10.78 Bn 71.88%
5 Merck 295.53 Bn 289.88 Bn 12.09 Bn 74.24%
6 Amgen 186.30 Bn 174.26 Bn 5.87 Bn 68.16%
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn 79.24%
8 Pfizer 146.09 Bn 133.32 Bn -1.21 Bn -51.69%
9 Bristol Myers Squibb 114.98 Bn 104.53 Bn 8.07 Bn 70.22%
10 Scilex Holding 48.31 Mn -101.62 Mn 4.15 Mn 48.29%

Historic Data

Download Data
DateValue
Mar 31, 2026 48.29%
Dec 31, 2025 45.99%
Sep 30, 2025 68.48%
Jun 30, 2025 66.94%
Mar 31, 2025 72.32%
Dec 31, 2024 68.52%
Sep 30, 2024 73.90%
Jun 30, 2024 73.18%
Mar 31, 2024 64.72%
Dec 31, 2023 66.42%
Sep 30, 2023 66.47%
Jun 30, 2023 66.80%
Mar 31, 2023 66.07%
Dec 31, 2022 62.14%
Sep 30, 2022 68.26%
Jun 30, 2022 80.71%
Mar 31, 2022 83.21%